Teleflex (TFX) Stock Overview
Designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, rest of the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
TFX Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Teleflex Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$119.18 |
| 52 Week High | US$143.32 |
| 52 Week Low | US$100.18 |
| Beta | 0.86 |
| 1 Month Change | 15.31% |
| 3 Month Change | 0.27% |
| 1 Year Change | -11.17% |
| 3 Year Change | -47.63% |
| 5 Year Change | -71.53% |
| Change since IPO | 31,712.55% |
Recent News & Updates
Recent updates
Teleflex: Selling, But How Much?
Dec 10Teleflex (NYSE:TFX) Has Announced A Dividend Of $0.34
Nov 09
Teleflex Incorporated (NYSE:TFX) Not Lagging Market On Growth Or Pricing
Oct 30These 4 Measures Indicate That Teleflex (NYSE:TFX) Is Using Debt Reasonably Well
Sep 11Results: Teleflex Incorporated Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 04Teleflex (NYSE:TFX) Has Announced A Dividend Of $0.34
Aug 03Teleflex Incorporated (NYSE:TFX) Not Lagging Market On Growth Or Pricing
Jul 10Investors Met With Slowing Returns on Capital At Teleflex (NYSE:TFX)
Jun 22Teleflex's (NYSE:TFX) Dividend Will Be $0.34
May 16Why Investors Shouldn't Be Surprised By Teleflex Incorporated's (NYSE:TFX) Low P/S
Mar 31Teleflex's (NYSE:TFX) Conservative Accounting Might Explain Soft Earnings
Mar 09Teleflex's Bold Transformation: Why I'm Skeptical On Value Creation
Mar 02Teleflex Incorporated: Compelling Only On One Metric
Dec 11Teleflex Reinvesting In Growth, But Valuation Isn't That Compelling
Aug 26
Innovation And Critical Acquisitions Propel Revenue Recovery
Expansion in geographic markets and new product introductions suggest ongoing innovation and revenue growth opportunities.Shareholder Returns
| TFX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 6.5% | -1.2% | -1.4% |
| 1Y | -11.2% | -8.3% | 18.2% |
Return vs Industry: TFX underperformed the US Medical Equipment industry which returned -8.3% over the past year.
Return vs Market: TFX underperformed the US Market which returned 18.2% over the past year.
Price Volatility
| TFX volatility | |
|---|---|
| TFX Average Weekly Movement | 6.5% |
| Medical Equipment Industry Average Movement | 7.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TFX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TFX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1943 | 14,100 | Stu Randle | www.teleflex.com |
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, rest of the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters.
Teleflex Incorporated Fundamentals Summary
| TFX fundamental statistics | |
|---|---|
| Market cap | US$5.40b |
| Earnings (TTM) | US$58.53m |
| Revenue (TTM) | US$1.99b |
Is TFX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TFX income statement (TTM) | |
|---|---|
| Revenue | US$1.99b |
| Cost of Revenue | US$869.26m |
| Gross Profit | US$1.12b |
| Other Expenses | US$1.06b |
| Earnings | US$58.53m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.32 |
| Gross Margin | 56.38% |
| Net Profit Margin | 2.94% |
| Debt/Equity Ratio | 87.0% |
How did TFX perform over the long term?
See historical performance and comparisonDividends
Does TFX pay a reliable dividends?
See TFX dividend history and benchmarks| Teleflex dividend dates | |
|---|---|
| Ex Dividend Date | Mar 06 2026 |
| Dividend Pay Date | Mar 31 2026 |
| Days until Ex dividend | 1 day |
| Days until Dividend pay date | 26 days |
Does TFX pay a reliable dividends?
See TFX dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/04 22:52 |
| End of Day Share Price | 2026/03/04 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Teleflex Incorporated is covered by 25 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Taylor | Barclays |
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |